StockData
GHRSNasdaqPharmaceutical PreparationsFiscal year ends December 31

GH Research PLC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 5, 2026
$18.28+0.13 (+0.72%)

Close on Oct 19, 2026

Market cap
$1.22B
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 5, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 6, 2026Before market open–$-0.23–
Q1 FY2026
Ended Mar 31, 2026
May 14, 2026Before market open–$-0.31–
Q4 FY2025
Ended Dec 31, 2025
Mar 5, 2026Before market open–––
Q3 FY2025
Ended Sep 30, 2025
Nov 6, 2025Before market open–$-0.23–
Q2 FY2025
Ended Jun 30, 2025
Aug 7, 2025Before market open–$-0.15–
Q1 FY2025
Ended Mar 31, 2025
May 8, 2025Before market open–$-0.19–
Q4 FY2024
Ended Dec 31, 2024
Feb 27, 2025Before market open–––
Q3 FY2024
Ended Sep 30, 2024
Nov 14, 2024Before market open–$-0.23–
Q2 FY2024
Ended Jun 30, 2024
Sep 3, 2024Before market open–$-0.20–
Q1 FY2024
Ended Mar 31, 2024
May 3, 2024Before market open–$-0.15–
Q4 FY2023
Ended Dec 31, 2023
Feb 29, 2024Before market open–––

Press releases

Announcements GH Research filed with the SEC